Remember that Ohio State study that linked omega-3s to prostate cancer? Well, here's your update to that.
Following up on the not-so-favorable results of a study that found omega-3 consumption may be linked to increased prostate cancer risk, the Journal of the National Cancer Institute brought together a handful of investigators involved in recent, similar prospective studies to reanalyze all of their data combined.
The combined analysis included 5098 subjects who were diagnosed with prostate cancer during studies and 6649 control subjects. The average follow-up time for each study was five years. Data dated as far back as the 2007 Physicians’ Health Study and as recent as the 2013 SELECT trial, the details of which are discussed in the first link above.
In this meta-analysis, while researchers observed elevated risks of prostate cancer in the highest quintile of EPA and DHA fatty acid consumption, a cause-and-effect relationship was not established for either, and heterogeneity was found amongst the studies. Interestingly enough, stearic acid was inversely associated with prostate cancer risk, and data on the remaining 11 fatty acids under investigation bore no connection to prostate cancer.
“There was no strong evidence that circulating fatty acids are important predictors of prostate cancer risk,” concluded the team. “It is not clear whether the modest associations of stearic, eicosapentaenoic (EPA), and docosapentaenoic acid (DHA) are causal.”
Robby Gardner
Associate Editor
Nutritional Outlook magazine
robby.gardner@ubm.com
Photo by ©iStockphoto.com/Brilt
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.